CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
By Mike Cherney SYDNEY--Australia-based pharmaceutical company CSL said its Phase 3 study into whether its CSL112 drug reduced the risk of cardiovascular...
New South Wales Mike Cherney Article Normal Biotechnology Services Cardiovascular Drugs Healthcare Life Sciences
Source: marketwatch.com